256 related articles for article (PubMed ID: 26751392)
1. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
2. Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones.
Aschim EL; Oldenburg J; Kristiansen W; Giwercman A; Witczak O; Fosså SD; Haugen TB
Hum Reprod; 2014 Dec; 29(12):2844-51. PubMed ID: 25336703
[TBL] [Abstract][Full Text] [Related]
3. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
[No Abstract] [Full Text] [Related]
4. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
5. Re: Single-Nucleotide Polymorphism in the 5-α-Reductase Gene (SRD5A2) is Associated with Increased Prevalence of Metabolic Syndrome in Chemotherapy-Treated Testicular Cancer Survivors.
Richie JP
J Urol; 2016 Dec; 196(6):1677-1678. PubMed ID: 27845109
[No Abstract] [Full Text] [Related]
6. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
7. Analysis of polymorphisms in the SRD5A2 gene and semen parameters in Estonian men.
Peters M; Saare M; Kaart T; Haller-Kikkatalo K; Lend AK; Punab M; Metspalu A; Salumets A
J Androl; 2010; 31(4):372-8. PubMed ID: 19926884
[TBL] [Abstract][Full Text] [Related]
8. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer.
de Haas EC; Zwart N; Meijer C; Nuver J; Boezen HM; Suurmeijer AJ; Hoekstra HJ; van der Steege G; Sleijfer DT; Gietema JA
J Clin Oncol; 2008 Apr; 26(11):1817-23. PubMed ID: 18398146
[TBL] [Abstract][Full Text] [Related]
9. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
[TBL] [Abstract][Full Text] [Related]
10. Early development of the metabolic syndrome after chemotherapy for testicular cancer.
de Haas EC; Altena R; Boezen HM; Zwart N; Smit AJ; Bakker SJ; van Roon AM; Postma A; Wolffenbuttel BH; Hoekstra HJ; van Leeuwen FE; Sleijfer DT; Gietema JA
Ann Oncol; 2013 Mar; 24(3):749-55. PubMed ID: 23131388
[TBL] [Abstract][Full Text] [Related]
11. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
12. Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.
van der Schoot GGF; Westerink NL; Lubberts S; Nuver J; Zwart N; Walenkamp AME; Wempe JB; Meijer C; Gietema JA
Eur J Cancer; 2016 May; 59():134-141. PubMed ID: 27033261
[TBL] [Abstract][Full Text] [Related]
13. Association between
Sun L; Zhou M; Liu T
Pharmazie; 2019 Feb; 74(2):125-128. PubMed ID: 30782264
[TBL] [Abstract][Full Text] [Related]
14. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
17. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
Li J; Coates RJ; Gwinn M; Khoury MJ
Am J Epidemiol; 2010 Jan; 171(1):1-13. PubMed ID: 19914946
[TBL] [Abstract][Full Text] [Related]
18. Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men.
Jiang J; Tang NL; Ohlsson C; Eriksson AL; Vandenput L; Liao C; Wang X; Chan FW; Kwok A; Orwoll E; Kwok TC; Woo J; Leung PC
Clin Chem; 2010 Nov; 56(11):1742-9. PubMed ID: 20855474
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of 17 β-hydroxysteroid dehydrogenase 3 and the risk of hypospadias.
Sata F; Kurahashi N; Ban S; Moriya K; Tanaka KD; Ishizuka M; Nakao H; Yahata Y; Imai H; Kakizaki H; Nonomura K; Kishi R
J Sex Med; 2010 Aug; 7(8):2729-38. PubMed ID: 20059664
[TBL] [Abstract][Full Text] [Related]
20. SRD5A2 gene polymorphisms affect the risk of breast cancer.
Francis A; Sarkar S; Pooja S; Surekha D; Rao DR; Rao L; Ramachandra L; Vishnupriya S; Satyamoorthy K; Thangaraj K; Rajender S
Breast; 2014 Apr; 23(2):137-41. PubMed ID: 24365257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
